Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
60Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $408.2K | $-9.91M | $-0.08 |
| 2024 | $674.0K | $-7.88M | $-0.01 |
| 2023 | $743.0K | $-7.63M | $-0.01 |
| 2022 | $810.0K | $-10.17M | $-0.03 |
| 2021 | $853.0K | $-12.60M | $-0.06 |
Social Signal Score
Earnings
Thu, Aug 27(in 11 days)
Consensus estimate $-0.33 per share
Typical surprise +88.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Mar 26$-5.97 vs $-27.00beat
- Thu, Aug 28$-0.00 vs $-4.15beat
- Mon, Apr 14$-0.10 vs $-0.10beat
- Thu, Mar 27$-0.00 vs $-0.24beat
- Thu, Jan 2$-0.27 vs $-0.27beat
- Thu, Aug 29$-0.00 vs $-0.36beat
Estimates and results for CANF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
CANFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsglobenewswire.com·3d ago·Negative
Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates Namodenoson Holds FDA Fast Track and U.S. and European Orphan Drug Designations; Piclidenoson and Namodenoson Are Advancing in Phase III Programs Ramat Gan, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, tod
View source ↗